ANI Pharmaceuticals (ANIP) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
2 figures withheld by our checks. Each blank figure names its reason.
12.6mn → 21.2mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
steady at 1.6% of revenue (−14.8% YoY).
$13.4M returned vs $171.4M of FCF in FY25. Buybacks + dividends covered by cash flow.
9¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 53.5% → 61.4%. Net margin 8.9% is more than double the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 1,041,343.0 | 883,366.0 | 614,376.0 | 486,816.0 | 316,385.0 | 216,136.0 | ▲43.8% | +42.2% |
Cost of revenue | 305,382.0 | 341,310.0 | 250,210.0 | 181,513.0 | 138,785.0 | 100,610.0 | ▲36.4% | +35.7% |
Gross profit | 735,961.0 | 542,056.0 | 364,166.0 | 305,303.0 | 177,600.0 | 115,526.0 | ▲48.8% | +47.2% |
Research & development | 50,605.0 | 51,664.0 | 44,581.0 | 34,286.0 | 22,318.0 | 11,369.0 | ▲15.9% | +46.0% |
Selling, general & admin | 342,968.0 | 317,745.0 | 249,636.0 | 161,697.0 | 124,044.0 | 84,294.0 | ▲27.3% | +39.3% |
Total operating expenses | 569,473.0 | 430,963.0 | 363,582.0 | 258,332.0 | 212,771.0 | 155,319.0 | ▲18.5% | +29.1% |
Operating incomefeeds ROC rank | 166,488.0 | 111,093.0 | 584.0 | 46,971.0 | −35,283.0 | −39,793.0 | ▲18922.8% | — |
Other income, net | −8,650.0 | −15,302.0 | −22,796.0 | −27,099.0 | −27,382.0 | −16,265.0 | — | — |
Pretax income | 157,838.0 | 95,791.0 | −22,212.0 | 19,872.0 | −62,665.0 | −56,058.0 | — | — |
Income tax | 40,996.0 | 17,454.0 | −3,690.0 | 1,093.0 | −14,769.0 | −13,455.0 | — | — |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 116,842.0 | 78,337.0 | −18,522.0 | 18,779.0 | −47,896.0 | −42,603.0 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 4.98 | 3.32 | −1.04 | 0.85 | −3.05 | −3.40 | — | — |
Diluted shares (mn) | 21.68 | 21.23 | 19.32 | 18.19 | 16.26 | 12.60 | ▲9.9% | +13.9% |
| Margins | ||||||||
Gross margin58th pct in Healthcare | 70.7% | 61.4% | 59.3% | 62.7% | 56.1% | 53.5% | ▲2.1pp | +7.9pp |
Operating margin | 16.0% | 12.6% | 0.1% | 9.6% | −11.2% | −18.4% | ▲12.5pp | +31.0pp |
Net margin70th pct in Healthcare | 11.2% | 8.9% | −3.0% | 3.9% | −15.1% | −19.7% | ▲11.9pp | +28.6pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was ANI Pharmaceuticals' revenue last fiscal year?
ANI Pharmaceuticals reported revenue of $883.4M in fiscal 2025, up 43.8% from fiscal 2024.
What was ANI Pharmaceuticals' net income?
ANI Pharmaceuticals reported net income of $78.3M in fiscal 2025, a net margin of 8.9%.

